dr donna h ryan glp 1 Ryan, MD | Authors Donna Ryan - Professor Emerita

Initial benefits often include smoother texture and improved hydration

renal infarction (approximately 50% kidney loss) after cumulative 27 mg exposure

The noise was constant, making it nearly impossible for her to focus during client meetings and keeping her awake night after night

By 2024, Ozempic had surpassed Trulicity, also approved for type 2 diabetes (not obesity) to make up the largest share of GLP-1 prescriptions and spending (39% in 2024)

In recent years, off-label use for weight loss has contributed to GLP-1 RAs shortages, limiting access for patients with diabetes

Membership of the Working P, Barker P, Creasey PE, Dhatariya K, Levy N, Lipp A, et al